# Embecta Corp.: financial statements, quarterly

EMBC · Nasdaq · CIK 1872789 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/embc.md) · [Financials](/companies/embc/financials.md) · [Filings](/companies/embc/filings.md) · [Insiders](/companies/embc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/embc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [282 d](/filings/0001872789-25-000036.md) | [277](/filings/0001872789-25-000006.md) | [287](/filings/0001872789-25-000012.md) | [273](/filings/0001872789-25-000029.md) | [286 d](/filings/0001872789-25-000036.md) | [262](/filings/0001872789-26-000009.md) | [259](/filings/0001872789-26-000017.md) | [296](/filings/0001872789-26-000033.md) | [264 d](/filings/0001872789-25-000036.md) | [261](/filings/0001872789-26-000009.md) | [222](/filings/0001872789-26-000017.md) | [272](/filings/0001872789-26-000033.md) |
| Cost of revenue | $m | [100 d](/filings/0001872789-25-000036.md) | [91.4](/filings/0001872789-25-000006.md) | [102](/filings/0001872789-25-000012.md) | [82.4](/filings/0001872789-25-000029.md) | [112 d](/filings/0001872789-25-000036.md) | [105](/filings/0001872789-26-000009.md) | [94.9](/filings/0001872789-26-000017.md) | [98.4](/filings/0001872789-26-000033.md) | [106 d](/filings/0001872789-25-000036.md) | [99.5](/filings/0001872789-26-000009.md) | [94.0](/filings/0001872789-26-000017.md) | [118](/filings/0001872789-26-000033.md) |
| Gross profit | $m | [182 d](/filings/0001872789-25-000036.md) | [186](/filings/0001872789-25-000006.md) | [185](/filings/0001872789-25-000012.md) | [190](/filings/0001872789-25-000029.md) | [174 d](/filings/0001872789-25-000036.md) | [157](/filings/0001872789-26-000009.md) | [164](/filings/0001872789-26-000017.md) | [197](/filings/0001872789-26-000033.md) | [159 d](/filings/0001872789-25-000036.md) | [162](/filings/0001872789-26-000009.md) | [128](/filings/0001872789-26-000017.md) | [153](/filings/0001872789-26-000033.md) |
| Research and development | $m | [23.6 d](/filings/0001872789-25-000036.md) | [20.2](/filings/0001872789-25-000006.md) | [18.4](/filings/0001872789-25-000012.md) | [20.4](/filings/0001872789-25-000029.md) | [19.8 d](/filings/0001872789-25-000036.md) | [20.3](/filings/0001872789-26-000009.md) | [8.0](/filings/0001872789-26-000017.md) | [4.4](/filings/0001872789-26-000033.md) | [4.6 d](/filings/0001872789-25-000036.md) | [4.6](/filings/0001872789-26-000009.md) | [5.4](/filings/0001872789-26-000017.md) | [5.6](/filings/0001872789-26-000033.md) |
| Selling, general and administrative | $m | [95.7 d](/filings/0001872789-25-000036.md) | [90.3](/filings/0001872789-25-000006.md) | [92.3](/filings/0001872789-25-000012.md) | [85.7](/filings/0001872789-25-000029.md) | [96.8 d](/filings/0001872789-25-000036.md) | [81.1](/filings/0001872789-26-000009.md) | [79.6](/filings/0001872789-26-000017.md) | [84.4](/filings/0001872789-26-000033.md) | [86.9 d](/filings/0001872789-25-000036.md) | [77.6](/filings/0001872789-26-000009.md) | [76.2](/filings/0001872789-26-000017.md) | [78.6](/filings/0001872789-26-000033.md) |
| Operating income | $m | [25.8 d](/filings/0001872789-25-000036.md) | [45.5](/filings/0001872789-25-000006.md) | [39.2](/filings/0001872789-25-000012.md) | [55.9](/filings/0001872789-25-000029.md) | [26.2 d](/filings/0001872789-25-000036.md) | [28.7](/filings/0001872789-26-000009.md) | [62.9](/filings/0001872789-26-000017.md) | [94.0](/filings/0001872789-26-000033.md) | [56.5 d](/filings/0001872789-25-000036.md) | [83.3](/filings/0001872789-26-000009.md) | [35.0](/filings/0001872789-26-000017.md) | [48.7](/filings/0001872789-26-000033.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.0) d](/filings/0001872789-25-000036.md) | [(5.8)](/filings/0001872789-25-000006.md) | [(19.0)](/filings/0001872789-25-000012.md) | [12.3](/filings/0001872789-25-000029.md) | [(21.6) d](/filings/0001872789-25-000036.md) | [(0.7)](/filings/0001872789-26-000009.md) | [12.3](/filings/0001872789-26-000017.md) | [26.7](/filings/0001872789-26-000033.md) | [2.6 d](/filings/0001872789-25-000036.md) | [14.8](/filings/0001872789-26-000009.md) | [13.6](/filings/0001872789-26-000017.md) | [6.5](/filings/0001872789-26-000033.md) |
| Net income | $m | [6.0 d](/filings/0001872789-25-000036.md) | [20.1](/filings/0001872789-25-000006.md) | [28.9](/filings/0001872789-25-000012.md) | [14.7](/filings/0001872789-25-000029.md) | [14.6 d](/filings/0001872789-25-000036.md) | [0.0](/filings/0001872789-26-000009.md) | [23.5](/filings/0001872789-26-000017.md) | [45.5](/filings/0001872789-26-000033.md) | [26.4 d](/filings/0001872789-25-000036.md) | [44.1](/filings/0001872789-26-000009.md) | [(4.1)](/filings/0001872789-26-000017.md) | [21.1](/filings/0001872789-26-000033.md) |
| Diluted EPS | $ per share | not reported | [0.35](/filings/0001872789-25-000006.md) | [0.50](/filings/0001872789-25-000012.md) | [0.25](/filings/0001872789-25-000029.md) | not reported | [0.00](/filings/0001872789-26-000009.md) | [0.40](/filings/0001872789-26-000017.md) | [0.78](/filings/0001872789-26-000033.md) | not reported | [0.74](/filings/0001872789-26-000009.md) | [(0.07)](/filings/0001872789-26-000017.md) | [0.36](/filings/0001872789-26-000033.md) |
| Basic EPS | $ per share | not reported | [0.35](/filings/0001872789-25-000006.md) | [0.50](/filings/0001872789-25-000012.md) | [0.25](/filings/0001872789-25-000029.md) | not reported | [0.00](/filings/0001872789-26-000009.md) | [0.40](/filings/0001872789-26-000017.md) | [0.78](/filings/0001872789-26-000033.md) | not reported | [0.75](/filings/0001872789-26-000009.md) | [(0.07)](/filings/0001872789-26-000017.md) | [0.36](/filings/0001872789-26-000033.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [326](/filings/0001872789-24-000037.md) | [299](/filings/0001872789-24-000006.md) | [300](/filings/0001872789-24-000019.md) | [275](/filings/0001872789-24-000028.md) | [268](/filings/0001872789-25-000036.md) | [210](/filings/0001872789-25-000006.md) | [209](/filings/0001872789-25-000012.md) | [231](/filings/0001872789-25-000029.md) | [226](/filings/0001872789-26-000033.md) | [201](/filings/0001872789-26-000009.md) | [185](/filings/0001872789-26-000017.md) | [215](/filings/0001872789-26-000033.md) |
| Current assets | $m | [749](/filings/0001872789-24-000037.md) | [720](/filings/0001872789-24-000006.md) | [710](/filings/0001872789-24-000019.md) | [781](/filings/0001872789-24-000028.md) | [761](/filings/0001872789-25-000036.md) | [667](/filings/0001872789-25-000006.md) | [643](/filings/0001872789-25-000012.md) | [682](/filings/0001872789-25-000029.md) | [631](/filings/0001872789-26-000033.md) | [620](/filings/0001872789-26-000009.md) | [608](/filings/0001872789-26-000017.md) | [705](/filings/0001872789-26-000033.md) |
| Total assets | $m | [1,214](/filings/0001872789-24-000037.md) | [1,218](/filings/0001872789-24-000006.md) | [1,200](/filings/0001872789-24-000019.md) | [1,268](/filings/0001872789-24-000028.md) | [1,285](/filings/0001872789-25-000036.md) | [1,150](/filings/0001872789-25-000006.md) | [1,120](/filings/0001872789-25-000012.md) | [1,157](/filings/0001872789-25-000029.md) | [1,091](/filings/0001872789-26-000033.md) | [1,064](/filings/0001872789-26-000009.md) | [1,029](/filings/0001872789-26-000017.md) | [1,265](/filings/0001872789-26-000033.md) |
| Current liabilities | $m | [354](/filings/0001872789-24-000037.md) | [327](/filings/0001872789-24-000006.md) | [310](/filings/0001872789-24-000019.md) | [371](/filings/0001872789-24-000028.md) | [374](/filings/0001872789-25-000036.md) | [298](/filings/0001872789-25-000006.md) | [259](/filings/0001872789-25-000012.md) | [276](/filings/0001872789-25-000029.md) | [262](/filings/0001872789-26-000033.md) | [235](/filings/0001872789-26-000009.md) | [247](/filings/0001872789-26-000017.md) | [420](/filings/0001872789-26-000033.md) |
| Long-term debt | $m | [1,594](/filings/0001872789-24-000037.md) | [1,593](/filings/0001872789-24-000006.md) | [1,592](/filings/0001872789-24-000019.md) | [1,591](/filings/0001872789-24-000028.md) | [1,565](/filings/0001872789-25-000036.md) | [1,535](/filings/0001872789-25-000006.md) | [1,509](/filings/0001872789-25-000012.md) | [1,459](/filings/0001872789-25-000029.md) | [1,389](/filings/0001872789-26-000033.md) | [1,353](/filings/0001872789-26-000009.md) | [1,317](/filings/0001872789-26-000017.md) | [1,316](/filings/0001872789-26-000033.md) |
| Current portion of debt | $m | [9.5](/filings/0001872789-24-000037.md) | [9.5](/filings/0001872789-24-000006.md) | [9.5](/filings/0001872789-24-000019.md) | [9.5](/filings/0001872789-24-000028.md) | [9.5](/filings/0001872789-25-000036.md) | [9.5](/filings/0001872789-25-000006.md) | [9.5](/filings/0001872789-25-000012.md) | [9.5](/filings/0001872789-25-000029.md) | [9.5](/filings/0001872789-26-000033.md) | [9.5](/filings/0001872789-26-000009.md) | [9.5](/filings/0001872789-26-000017.md) | [139](/filings/0001872789-26-000033.md) |
| Shareholders' equity | $m | [(822)](/filings/0001872789-25-000036.md) | [(794)](/filings/0001872789-25-000012.md) | [(770)](/filings/0001872789-25-000029.md) | [(764)](/filings/0001872789-25-000029.md) | [(738)](/filings/0001872789-26-000033.md) | [(769)](/filings/0001872789-26-000017.md) | [(736)](/filings/0001872789-26-000033.md) | [(670)](/filings/0001872789-26-000033.md) | [(651)](/filings/0001872789-26-000033.md) | [(613)](/filings/0001872789-26-000017.md) | [(626)](/filings/0001872789-26-000033.md) | [(613)](/filings/0001872789-26-000033.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [29.6 d](/filings/0001872789-25-000036.md) | [(13.1)](/filings/0001872789-25-000006.md) | [24.3 d](/filings/0001872789-25-000012.md) | [(2.1) d](/filings/0001872789-25-000029.md) | [26.6 d](/filings/0001872789-25-000036.md) | [(5.3)](/filings/0001872789-26-000009.md) | [31.8 d](/filings/0001872789-26-000017.md) | [81.2 d](/filings/0001872789-26-000033.md) | [84.0 d](/filings/0001872789-25-000036.md) | [17.2](/filings/0001872789-26-000009.md) | [31.1 d](/filings/0001872789-26-000017.md) | [41.8 d](/filings/0001872789-26-000033.md) |
| Capital expenditure | $m | [9.2 d](/filings/0001872789-25-000036.md) | [2.7](/filings/0001872789-25-000006.md) | [3.4 d](/filings/0001872789-25-000012.md) | [9.7 d](/filings/0001872789-25-000029.md) | [0.0 d](/filings/0001872789-25-000036.md) | [1.5](/filings/0001872789-26-000009.md) | [0.1 d](/filings/0001872789-26-000017.md) | [0.4 d](/filings/0001872789-26-000033.md) | [7.3 d](/filings/0001872789-25-000036.md) | [0.6](/filings/0001872789-26-000009.md) | [0.5 d](/filings/0001872789-26-000017.md) | [1.1 d](/filings/0001872789-26-000033.md) |
| Dividends paid | $m | [8.6 d](/filings/0001872789-25-000036.md) | [8.6](/filings/0001872789-25-000006.md) | [8.6 d](/filings/0001872789-25-000012.md) | [8.6 d](/filings/0001872789-25-000029.md) | [8.7 d](/filings/0001872789-25-000036.md) | [8.8](/filings/0001872789-26-000009.md) | [8.7 d](/filings/0001872789-26-000017.md) | [8.7 d](/filings/0001872789-26-000033.md) | [8.8 d](/filings/0001872789-25-000036.md) | [8.9](/filings/0001872789-26-000009.md) | [8.9 d](/filings/0001872789-26-000017.md) | [0.6 d](/filings/0001872789-26-000033.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [57.5](/filings/0001872789-24-000006.md) | [57.5](/filings/0001872789-24-000019.md) | [57.6](/filings/0001872789-24-000028.md) | [57.6](/filings/0001872789-25-000006.md) | [57.8](/filings/0001872789-25-000012.md) | [57.8](/filings/0001872789-25-000029.md) | [58.6](/filings/0001872789-26-000009.md) | [58.5](/filings/0001872789-26-000017.md) | [58.5](/filings/0001872789-26-000033.md) | [59.3](/filings/0001872789-26-000009.md) | [59.3](/filings/0001872789-26-000017.md) | [58.5](/filings/0001872789-26-000033.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 56,659,599 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001872789-26-000033.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.